Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, tolerability and safety of NVA237 compared to tiotropium
when added on to fluticasone/salmeterol in patients with chronic obstructive pulmonary
disease.